Silvio Veraldi

Dr. Silvio Veraldi


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2020 in Digestive and Liver Disease
Verified
Journal Article
Closed access
SVSilvio Veraldi
Silvio Veraldi
APandrea pietrobattista
andrea pietrobattista
DLDaniela Liccardo
Daniela Liccardo
MBMaria Sole Basso
Maria Sole Basso
AMAntonella Mosca
Antonella Mosca
MCManila Candusso
Manila Candusso

18 October 2022 in Frontiers in Pediatrics
Verified
Journal Article
Open access
SVSilvio Veraldi
Silvio Veraldi
APAndrea Pietrobattista
Andrea Pietrobattista
GSGiovanna Soglia
Giovanna Soglia
LMLidia Monti
Lidia Monti
TATommaso Alterio
Tommaso Alterio
GMGiuseppe Maggiore
Giuseppe Maggiore
Sarcopenia is a clinical condition characterized by a reduction in muscle mass, which typically affects adult patients; however, it has recently been recognized in pediatric literature. Few studies in children with chronic liver disease (CLD) undergoing liver transplantation (LT) have investigated the role of sarcopenia, with controversial results. The aim of our study was to assess the prevalence and impact of sarcopenia among children with CLD who are candidates for LT. We conducted a retrospective, single-center study at Bambino Gesù Children's Hospital (Rome, Italy) from July 2016 to July 2021, evaluating all children (0–16 years old) with CLD listed for LT with an abdomen computed tomography imaging available before LT. The total psoas muscle surface area (t-PMSA) was defined as the sum of left and right psoas muscle surface area measured at L4–L5 on axial images. The t-PMSA z-score was calculated according to reference data, and sarcopenia was defined as a t-PMSA z-score of ≤−2 (1–16 years) or a psoas muscle index [PMI; PMI = t-PMSA/(100 × BSA)] of <50th percentile of the population examined (<1 year). Clinical, laboratory, and LT outcome data were collected from all the patients with CLD. 27 out 48 (56%) of the patients aged 1–16 years were sarcopenic. No differences were noted in anthropometrics, nutritional support, liver function tests, model for ESLD (MELD), or pediatric ESLD (PELD) scores between patients with and without sarcopenia. The former showed a higher prevalence of respiratory complications (66.7% vs. 42.1%) and need for inotropes (40.7% vs. 10.8%) after LT. Among patients aged 0–1 years (n: 36), those with reduced muscle mass (50%) had a longer hospitalization time (44 vs. 24 days) and higher incidences of multi-organ failure syndrome (38.9% vs. 0%) and intensive care unit-related infections (61.1% vs. 27.8%) compared to those with greater muscle mass. t-PMSA and PMI were statistically significant predictors of LT outcomes. Sarcopenia is a reliable index of frailty in children with CLD, as its presence is associated with the risk of a more challenging LT. Future studies will have to investigate the functional aspects of sarcopenia and conceive preventive measures of muscle wasting in CLD patients.

17 March 2023 in Genes
Verified
Journal Article
Open access
PDF file
APandrea pietrobattista
andrea pietrobattista
LVLuca Della Volpe
Luca Della Volpe
PFPaola Francalanci
Paola Francalanci
LTLorenzo Figà Talamanca
Lorenzo Figà Talamanca
LMLidia Monti
Lidia Monti
GMGiuseppe Maggiore
Giuseppe Maggiore
Zhu–Tokita–Takenouchi–Kim (ZTTK) syndrome, an intellectual disability syndrome first described in 2016, is caused by heterozygous loss-of-function variants in SON. Haploinsufficiency in SON may affect multiple genes, including those involved in the development and metabolism of multiple organs. Considering the broad spectrum of SON functions, it is to be expected that pathogenic variants in this gene can cause a wide spectrum of clinical symptoms. We present an additional ZTTK syndrome case due to a de novo heterozygous variant in the SON gene (c.5751_5754delAGTT). The clinical manifestations of our patient were similar to those present in previously reported cases; however, the diagnosis of ZTTK syndrome was delayed for a long time and was carried out during the diagnostic work-up of significant chronic liver disease (CLD). CLD has not yet been reported in any series; therefore, our report provides new information on this rare condition and suggests the expansion of the ZTTK syndrome phenotype, including possible liver involvement. Correspondingly, we recommend screening patients with SON variants specifically for liver involvement from the first years of life. Once the CLD has been diagnosed, an appropriate follow-up is mandatory, especially considering the role of SON as an emerging player in cancer development. Further studies are needed to investigate the role of SON haploinsufficiency as a downregulator of essential genes, thus potentially impairing the normal development and/or functions of multiple organs.

27 April 2020 in Clinica Chimica Acta
Verified
Journal Article
Closed access
APandrea pietrobattista
andrea pietrobattista
SVSilvio Veraldi
Silvio Veraldi
MCManila Candusso
Manila Candusso
MBMaria Sole Basso
Maria Sole Basso
DLDaniela Liccardo
Daniela Liccardo
CDCarlo Dionisi-Vici
Carlo Dionisi-Vici

3 February 2026 in Pediatric Reports
Verified
Journal Article
Open access
PDF file
MSMarco Sciveres
Marco Sciveres
SVSilvio Veraldi
Silvio Veraldi
FCFrancesco Cirillo
Francesco Cirillo
GMGiuseppe Maggiore
Giuseppe Maggiore
Cholestatic diseases in children represent a heterogeneous group of disorders that, with few exceptions, have no cure. For decades, off-label drugs and/or drugs with little evidence of efficacy have been used to treat pruritus or as supportive therapy. In recent years, a family of molecules known as bile acid transporter inhibitors (IBATis) has been developed, with two of these being approved for treating pruritus in progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS). Blocking the ileal reabsorption of bile acids (BAs) lowers serum levels. This contributes to reducing cholestatic pruritus. Such a mechanism of action may also have a potential benefit in other cholestatic diseases and even in the consequences of chronic cholestasis. This is a narrative review of the literature, including the most recent communications, to summarize data on the efficacy and safety of IBATis in the treatment of pruritus in PFIC and ALGS in children, including a description of the latest results from their use in a real-world setting. Reports on off-label use and experiences in adults are also discussed. This review aims to help physicians understand the potential and limitations of these new drugs in the treatment of cholestatic pruritus.

1 November 2019 in Digestive and Liver Disease
Verified
Journal Article
Closed access
SVSilvio Veraldi
Silvio Veraldi
APAndrea Pietrobattista
Andrea Pietrobattista
DLDaniela Liccardo
Daniela Liccardo
MBMaria Sole Basso
Maria Sole Basso
AMAntonella Mosca
Antonella Mosca
MCManila Candusso
Manila Candusso